Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Hosted on MSN2d
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...
MedPage Today4d
Coffee and Heart, Metabolic Risks; What Drives Doctors Away; Ozempic for $100?
The FDA approved pembrolizumab (Keytruda) with chemotherapy as first-line treatment ... said major generic drugmakers told ...
Targeted Oncology4d
Low-Dose Pembrolizumab Shows Promise vs Standard Dose in Stage IV NSCLC
A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...